Epiao Adverse Reactions

Common reactions: headache, fever and fatigue occur occasionally at the beginning of Epoetin Alfa (EPIAO) therapy. Myalgia and arthralgia have been observed rarely. Most of these symptoms can be corrected by expectant treatments and the therapy can be continued. If symptoms persist, the therapy should be discontinued.
Allergic reactions: There have been no reports of serious allergic reactions or anaphylaxis associated with erythropoietin administration during clinical trials. Skin rashes and urticaria have been observed rarely and when reported have generally been mild and transient in nature. A low dose administration prior to the full dose treatment is recommended for the patients starting or resuming the treatment of Epoetin Alfa (EPIAO). Any abnormality should be treated appropriately and the Epoetin Alfa (EPIAO) administration should be discontinued.
Cardio-cerebral vascular system: Increases in blood pressure, deterioration of hypertension, headache induced by hypertensive encephalopathy and seizures have been reported in clinical trials. Therefore, blood pressure should be monitored carefully and if necessary, the dose of Epoetin Alfa (EPIAO) should be adjusted/terminated and hypotensive agents may be used.
Blood system: With the increase of Hct due to administration of Epoetin Alfa (EPIAO), the blood viscosity can be increased; measures should be taken to prevent thrombosis.
Liver: Enhancement of GOT and GPT are rarely observed.
Gastrointestinal: Anorexia, nausea, vomiting and diarrhea occur rarely.